About Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our foundation
in scientific research to our focus on clinical trials, and now our
commercial expansion, we are evolving and growing rapidly. Amarin
has offices in Bridgewater, New Jersey in the United States, Dublin
in Ireland, Zug in Switzerland, and other countries in Europe as
well as commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.
Forward-Looking Statements
This communication contains forward-looking statements which are
made pursuant to U.S. federal securities law, including beliefs
about Amarin’s key achievements in 2022 and the potential impact
and outlook for achievements in 2023 and beyond; Amarin’s 2023
financial outlook and cash position; Amarin’s strategic direction
and actions management has taken to stabilize our U.S. business and
position Amarin for growth and value creation; the runway for
growth as Amarin’s strategic focus shifts toward expanding the
business in Europe and other international markets; objectives of
Amarin’s cost reduction program and other cash preservation
initiatives, Amarin’s commitment to identifying and rigorously
evaluating new highly qualified, independent candidates for
Amarin’s Board of Directors, including full, comprehensive
evaluation of Sarissa Capital Management LP’s proposed nominees;
and the overall potential and future success of VASCEPA (marketed
as VAZKEPA in Europe) and Amarin generally. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. A further list and description of these
risks, uncertainties and other risks associated with an investment
in Amarin can be found in Amarin’s filings with the U.S. Securities
and Exchange Commission, including Amarin’s annual report on
Form 10-K for the
full year ended 2021. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they are made. Amarin
undertakes no obligation to update or revise the information
contained in its forward-looking statements, whether as a result of
new information, future events or circumstances or otherwise.
Amarin’s forward-looking statements do not reflect the potential
impact of significant transactions the company may enter into, such
as mergers, acquisitions, dispositions, joint ventures or any
material agreements that Amarin may enter into, amend or
terminate.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the
company website (www.amarincorp.com) and the investor relations
website (investor.amarincorp.com), including but not limited to
investor presentations and FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Additional Information
Amarin, its directors and certain of its executive officers may be
deemed to be participants in the solicitation of proxies from
shareholders in connection with the matters to be considered at any
special meeting called at the request of Sarissa. If a special
meeting is convened, the Company intends to file a proxy statement
and WHITE proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with any such solicitation of
proxies from shareholders. SHAREHOLDERS ARE STRONGLY ENCOURAGED TO
READ ANY SUCH PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD
WHEN THEY BECOME AVAILABLE AS THEY WOULD CONTAIN IMPORTANT
INFORMATION. Information regarding the ownership of the Company’s
directors and executive officers in Company stock and other
securities is included in their SEC filings on Forms 3, 4, and 5,
which can be found through the Company’s website
(www.amarincorp.com) in the section “Investors” or through the
SEC’s website at www.sec.gov. Additional information about Amarin’s
directors and executive officers and their interests is set forth
in Amarin’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, which was filed with the SEC on
March 3, 2021, and amended on May 2, 2021, as well as
Amarin’s proxy statement for its 2022 Annual General Meeting of
Shareholders, which was filed